Acute Myeloid Leukemia, NPM1-Mutated

1. Disease Information

1.1 Concise overview

NPM1-mutated AML is a genetically defined AML subtype characterized by somatic mutations in NPM1 that produce an aberrantly cytoplasmic nucleophosmin protein (“NPM1c”), and it is the largest molecular subgroup of adult AML. (falini2024criteriafordiagnosis pages 1-2)

Current classification concept: recent WHO/ICC schemes treat NPM1 mutation as AML‑defining, with differences in blast thresholds (see below). (patel2024npm1mutatedacutemyeloid pages 1-2, falini2024criteriafordiagnosis pages 5-6, shimony2023acutemyeloidleukemia pages 5-6)

1.2 Common synonyms / alternative names

• “AML with mutated NPM1”
• “NPM1-mutated AML”, “NPM1mut AML”, “NPM1+ AML” (falini2024criteriafordiagnosis pages 1-2)

1.3 Key identifiers (available from retrieved sources)

• WHO/ICC entity: AML with mutated NPM1 (AML defined by genetic abnormality) (falini2024criteriafordiagnosis pages 5-6, shimony2023acutemyeloidleukemia pages 5-6)
• Risk stratification: ELN 2022 incorporates NPM1 and FLT3 testing as mandatory for genetic risk stratification. (falini2024criteriafordiagnosis pages 1-2)

Not retrieved in this run: OMIM, Orphanet, MeSH, ICD-10/ICD-11, and a disease-specific MONDO identifier for “NPM1-mutated AML”.

1.4 Classification details (WHO 2022 vs ICC 2022; ELN 2022)

• Blast threshold (WHO 5th edition / WHO 2022): WHO permits diagnosing NPM1‑mutated AML irrespective of blast percentage (WHO “AML defined by genetic abnormalities” does not specify a blast cut-off). (falini2024criteriafordiagnosis pages 5-6, shimony2023acutemyeloidleukemia pages 5-6)
• Blast threshold (ICC 2022): ICC requires ≥10% blasts for AML with recurrent genetic abnormalities, including NPM1-mutated AML. (falini2024criteriafordiagnosis pages 5-6, shimony2023acutemyeloidleukemia pages 5-6)
• ELN 2022 genetic risk rules relevant to NPM1:
• NPM1 mutation without FLT3-ITD → favorable risk. (falini2024criteriafordiagnosis pages 5-6)
• NPM1 mutation with FLT3-ITD → intermediate risk regardless of FLT3-ITD allelic ratio. (falini2024criteriafordiagnosis pages 5-6, sargas2023comparisonofthe pages 1-2, lachowiez2023comparisonandvalidation pages 1-2)
• Adverse cytogenetics can override; “NPM1 mutated AML with adverse cytogenetic abnormalities will be classified as adverse risk.” (shimony2023acutemyeloidleukemia pages 5-6)

Table: This table summarizes the current naming, classification framework, blast-threshold differences, and headline epidemiology figures for acute myeloid leukemia with mutated NPM1. It is useful for quickly aligning WHO 2022, ICC 2022, and ELN 2022 terminology and risk-stratification rules.

2. Etiology

2.1 Disease causal factors (genetic/mechanistic)

• The defining lesion is a somatic NPM1 mutation, usually an exon 12 frameshift insertion affecting the C‑terminus; this creates aberrant cytoplasmic localization of mutant nucleophosmin (NPM1c). (patel2024npm1mutatedacutemyeloid pages 1-2, chin2023targetingandmonitoring pages 1-2)
• Mechanistically, NPM1-mutated AML depends on a characteristic transcriptional program with HOX/MEIS1 overexpression linked to NPM1c biology. (patel2024npm1mutatedacutemyeloid pages 1-2, falini2024criteriafordiagnosis pages 1-2)

2.2 Risk factors

Genetic (somatic co-mutations / disease biology modifiers) - Co-mutations are common and clinically important; across cohorts, recurrent co-mutations include FLT3 (especially FLT3-ITD), DNMT3A, WT1, and others, with prognostic impact (see Prognosis). (othman2024molecularclinicaland pages 1-5)

Environmental / iatrogenic - Therapy-related AML (t‑AML) can carry NPM1 mutations. A diagnostic-focused review notes that therapy-related NPM1‑mutated AML comprises ≈15% of therapy-related AMLs and, if FLT3-ITD negative, is considered ELN favorable with post‑remission decisions guided by MRD. (falini2024criteriafordiagnosis pages 5-6)

2.3 Protective factors

No specific protective (genetic or environmental) factors were retrieved in the cited evidence for the NPM1-mutated AML subtype.

2.4 Gene–environment interactions

No gene–environment interaction evidence specific to NPM1-mutated AML was retrieved in this run.

3. Phenotypes

3.1 Core clinical and pathologic phenotype (with selected frequencies)

Common presentation overlaps with AML generally (cytopenias, infections, bleeding), but NPM1-mutated AML has recurrent clinicopathologic patterns: - Bone marrow: typically markedly hypercellular. (falini2024criteriafordiagnosis pages 1-2) - Differentiation: often myelomonocytic/monocytic (FAB M4/M5 predominance; other FAB categories can occur). (falini2024criteriafordiagnosis pages 1-2) - Immunophenotype: typically no/low CD34 expression; a 2024 cohort paper states “the vast majority of NPM1m AML cases are therefore CD34‑negative”. (falini2024criteriafordiagnosis pages 1-2, papadopoulou2024characteristicsandprognosis pages 1-2) - Extramedullary disease: commonly reported, particularly skin involvement, and IHC can help detect such involvement. (falini2024criteriafordiagnosis pages 1-2) - Demographics: “female predominance” is noted in diagnostic reviews. (falini2024criteriafordiagnosis pages 1-2)

3.2 “APL-like” phenotype subset

A subset of NPM1‑mutated AML may show a “double negative” CD34−/HLA‑DR− immunophenotype that can mimic acute promyelocytic leukemia (APL) at presentation, necessitating rapid exclusion of PML::RARA rearrangement. (papadopoulou2024characteristicsandprognosis pages 1-2)

3.3 Suggested HPO terms (non-exhaustive; for knowledge-base tagging)

These are ontology suggestions (not direct extractions from a single cited ontology resource in this run): - Anemia (HP:0001903) - Thrombocytopenia (HP:0001873) - Leukocytosis (HP:0001974) - Neutropenia (HP:0001875) - Recurrent infections (HP:0002719) - Abnormal bleeding (HP:0001892) - Bone marrow hypercellularity (commonly mapped to marrow hypercellularity concepts; exact HPO mapping requires ontology lookup) - Extramedullary hematopoiesis / myeloid sarcoma (ontology mapping requires curation)

4. Genetic / Molecular Information

4.1 Causal gene

• Primary causal/defining gene: NPM1 (nucleophosmin 1). (falini2024criteriafordiagnosis pages 1-2)

4.2 Pathogenic variant spectrum (high-level)

• Variants are typically small insertions causing a C‑terminal frameshift and acquisition of a nuclear export signal, producing NPM1c. (chin2023targetingandmonitoring pages 1-2)
• Common mutation “types” (A/B/D) are described as exon‑12 insertion variants; one review provides approximate distribution: Type A ~72%, Type B ~12%, Type D ~4%. (chin2023targetingandmonitoring pages 1-2)

Somatic vs germline: the defining NPM1 lesion is described as somatic in AML series/reviews. (patel2024npm1mutatedacutemyeloid pages 1-2)

Population allele frequencies: not retrieved (these are somatic leukemia variants and are generally absent from germline population databases).

4.3 Co-mutations as molecular modifiers (selected)

In a large prospective trial cohort (NCRI AML17/AML19; n=1357), independent adverse baseline associations for overall survival included: FLT3-ITD (HR 1.28), DNMT3A (HR 1.65), WT1 (HR 1.74), and non‑ABD NPM1 mutations (HR 1.64). (othman2024molecularclinicaland pages 1-5)

4.4 Chromosomal abnormalities

NPM1-mutated AML is enriched in normal karyotype AML (a large fraction of NK-AML cases). (patel2024npm1mutatedacutemyeloid pages 1-2, falini2024criteriafordiagnosis pages 1-2)

4.5 Epigenetic / chromatin-level regulation (2023–2024 primary data)

Recent mechanistic work supports NPM1 mutation as a chromatin-associated neomorphic driver of the HOX program, including cooperation with KMT2A/MLL1 and maintenance of active chromatin at HOX loci. (patel2024npm1mutatedacutemyeloid pages 3-4)

A 2023 primary study additionally links NPM1C+ to 3D genome architecture changes (CTCF/TAD remodeling) that strengthen TADs at HOXA/B and PBX3 loci and weaken TADs at cell-cycle inhibitor loci (e.g., Cdkn1a/p21), supporting proliferation and differentiation block. (lai2023npm1mutationreprograms pages 1-3)

5. Mechanism / Pathophysiology

5.1 Causal chain (conceptual)

1. Somatic NPM1 frameshift mutation creates a C‑terminal neo‑sequence with nuclear export features →
2. Mutant NPM1 (NPM1c) mislocalizes to cytoplasm in an XPO1/exportin-1 dependent manner →
3. NPM1c engages nuclear/chromatin programs (and may mislocalize other factors), maintaining an abnormal transcriptional state →
4. HOX/MEIS1 transcriptional program is enforced, supporting self-renewal / differentiation arrest →
5. Myeloid differentiation block and clonal expansion manifest clinically as AML with characteristic monocytic/myelomonocytic phenotypes. (patel2024npm1mutatedacutemyeloid pages 1-2, falini2024criteriafordiagnosis pages 1-2, lai2023npm1mutationreprograms pages 1-3)

5.2 Pathways and cellular processes (selected)

• HOX/MEIS1 axis / menin–KMT2A dependency: NPM1-mutated cells rely on overexpression of HOX/MEIS1, which provides rationale for menin inhibitors. (patel2024npm1mutatedacutemyeloid pages 1-2, falini2024criteriafordiagnosis pages 1-2)
• Nuclear export (XPO1/CRM1): NPM1c localization depends on XPO1; inhibition can relocalize NPM1c and promote differentiation. (patel2024npm1mutatedacutemyeloid pages 8-9)
• 3D genome organization (CTCF/TADs): NPM1C+ can reshape CTCF-defined TAD topology, linking mutation to chromatin architecture and HOX activation. (lai2023npm1mutationreprograms pages 1-3)

5.3 Suggested GO and CL terms (for annotation; requires ontology validation)

• GO Biological Process (suggestions):
• hematopoietic cell differentiation
• myeloid cell differentiation
• regulation of transcription by RNA polymerase II
• chromatin organization / regulation of chromatin architecture
• nuclear export
• Cell Ontology (CL) (suggestions):
• hematopoietic stem cell
• myeloid progenitor cell
• monocyte
• myeloblast

6. Anatomical Structures Affected

Primary site: bone marrow hematopoietic tissue. (falini2024criteriafordiagnosis pages 1-2)

Peripheral blood involvement: circulating blasts/leukocytosis can occur, especially with RAS/FLT3 co-mutations. (falini2024criteriafordiagnosis pages 1-2)

Extramedullary involvement: skin and other sites (myeloid sarcoma) may be involved; mutant NPM1 IHC can support identification. (falini2024criteriafordiagnosis pages 1-2, patel2024npm1mutatedacutemyeloid pages 2-3)

Suggested UBERON terms (requires ontology lookup): bone marrow; blood; skin.

7. Temporal Development

• Typical onset: adult-onset AML; NPM1 mutations are common in adults and less common in children (2–8%). (falini2024criteriafordiagnosis pages 1-2)
• Course: acute presentation; relapse risk remains substantial even in this generally favorable subtype, motivating MRD monitoring and risk-adapted post-remission therapy. (othman2024molecularclinicaland pages 1-5, othman2024molecularmrdis pages 1-2)

8. Inheritance and Population

8.1 Epidemiology (mutation frequency within AML)

• NPM1 mutations occur in ~30–35% of adult AML and 50–60% of normal-karyotype AML; they are less frequent in children (2–8%). (falini2024criteriafordiagnosis pages 1-2)

8.2 Inheritance

• The defining lesion is somatic; a Mendelian inheritance pattern is not applicable to the AML entity itself in most cases. (patel2024npm1mutatedacutemyeloid pages 1-2)

9. Diagnostics

9.1 Recommended core molecular testing

• Determination of NPM1 and FLT3 mutational status is “a mandatory step” for ELN 2022 genetic risk stratification. (falini2024criteriafordiagnosis pages 1-2)

9.2 Diagnostic modalities

• Molecular techniques (e.g., sequencing-based detection) and immunohistochemistry for cytoplasmic NPM1c can be combined to solve difficult diagnostic problems (including certain atypical mutations). (falini2024criteriafordiagnosis pages 1-2)
• Flow cytometry: useful for immunophenotyping, but multiparameter flow MRD may be challenging to interpret in this subtype. (patel2024npm1mutatedacutemyeloid pages 1-2)

9.3 MRD monitoring (NPM1 as an MRD marker)

NPM1 mutant transcript burden closely tracks disease status and is suited to high-sensitivity MRD monitoring. (patel2024npm1mutatedacutemyeloid pages 1-2)

A key 2024 real-world analysis (venetoclax-based, nonintensive therapy) reported: - BM MRD negativity 25% by cycle 2; 47% by cycle 4; 50% by cycle 6. (othman2024molecularmrdis pages 1-2) - 2-year OS 84% if MRD-negative by cycle 4 vs 46% if MRD-positive. (othman2024molecularmrdis pages 1-2)

Direct abstract quote (MRD utility): “A total of 44 patients (58%) achieved bone marrow (BM) MRD negativity…” and “Patients achieving BM MRD negativity by the end of cycle 4 had 2-year overall of 84% compared with 46% if MRD was positive.” (othman2024molecularmrdis pages 1-2)

9.4 Visual evidence: MRD-based monitoring/decision algorithm

An MRD monitoring algorithm for intensive chemotherapy (including management of “MRD relapse”) is provided in Figure 4 of Falini & Dillon 2024. (falini2024criteriafordiagnosis media 3d972561)

10. Outcome / Prognosis

10.1 Baseline prognostic factors (intensively treated cohorts)

In a large prospective analysis of NPM1-mutated AML (NCRI AML17/AML19; n=1357), independent adverse factors for overall survival included FLT3-ITD, DNMT3A, WT1, and non‑ABD NPM1 mutation classes, and these were strongly associated with MRD positivity. (othman2024molecularclinicaland pages 1-5)

10.2 Response depth (MRD) as a major determinant

• Post-induction MRD negativity is emphasized as a major outcome determinant in NPM1-mutated AML, and MRD integration can guide post-remission therapy decisions including transplant. (falini2024criteriafordiagnosis pages 1-2, othman2024molecularclinicaland pages 1-5)
• In venetoclax-based nonintensive therapy, RT‑qPCR MRD negativity was the strongest prognostic factor in multivariable analysis and identified a subgroup with very favorable 2‑year OS (84%). (othman2024molecularmrdis pages 1-2)

11. Treatment

11.1 Standard-of-care frameworks (context)

• Standard AML backbones (intensive induction, consolidation, and/or allogeneic HSCT depending on risk/MRD) remain foundational; venetoclax + hypomethylating agent (HMA) or low-dose cytarabine (LDAC) are widely used in older/unfit patients and show high efficacy in NPM1-mutated disease. (shukla2024molecularfeaturesand pages 5-6, othman2024molecularmrdis pages 1-2)

11.2 MRD-directed and relapse-preemptive strategies (2024)

The prospective VALDAC phase II study demonstrates a real-world implementation of treating molecular MRD relapse or oligoblastic relapse with venetoclax+LDAC, with mutant NPM1 comprising 77% of MRD markers and MRD-negative remission achieved in 46% by cycle 2 in the MRD cohort. (tiong2024targetingmolecularmeasurable pages 1-2)

Direct abstract quote (VALDAC): “By cycle 2 in the MRD relapse cohort, a log10 reduction in MRD was observed in 69%; 46% achieved MRD negative remission.” (tiong2024targetingmolecularmeasurable pages 1-2)

11.3 Targeted therapy: Menin inhibitors (revumenib; emerging class)

A seminal first-in-human trial established menin inhibition as an actionable strategy in susceptible leukemias (including NPM1-mutant):

Direct abstract quote (Nature 2023): “therapy with revumenib was associated with a low frequency of grade 3 or higher treatment-related adverse events and a 30% rate of complete remission or complete remission with partial haematologic recovery (CR/CRh)… Asymptomatic prolongation of the QT interval… was identified as the only dose-limiting toxicity.” (issa2023themenininhibitor pages 1-2)

Quantitatively, in 60 evaluable patients with KMT2A-rearranged or NPM1-mutant disease, ORR was 53%, CR/CRh 30%, and MRD negativity among CR/CRh was 78%. (issa2023themenininhibitor pages 4-4)

11.4 Current applications / late-stage clinical development (Phase 3)

Multiple Phase 3 programs are actively evaluating adding menin inhibitors to standard regimens in newly diagnosed genetically selected AML: - Revumenib + intensive chemotherapy vs placebo (newly diagnosed NPM1-mutated AML): NCT07211958; Phase 3; estimated n=468; primary endpoints include event-free survival and MRD CR rate. (NCT07211958 chunk 1) - Revumenib + azacitidine + venetoclax vs placebo (newly diagnosed NPM1-mutated or KMT2A-rearranged AML, intensive-ineligible): NCT06652438; Phase 3; estimated n≈415. (NCT06652438 chunk 1) - Ziftomenib + (venetoclax+azacitidine) or + (7+3) vs placebo in untreated NPM1-mutated/KMT2A-rearranged AML: NCT07007312; Phase 3; estimated n=1300. (NCT07007312 chunk 1)

Table: This table summarizes high-value recent clinical evidence and current Phase 3 implementation studies for NPM1-mutated AML, spanning MRD-guided venetoclax use, preemptive relapse treatment, menin inhibition with revumenib, and active registrational trials. It is useful for comparing outcomes, safety signals, and real-world translational applications across the rapidly evolving 2023-2025 landscape.

11.5 Suggested MAXO terms (treatment action ontology; suggestions)

• induction chemotherapy
• consolidation chemotherapy
• allogeneic hematopoietic stem cell transplantation
• measurable residual disease monitoring
• BCL2 inhibitor therapy (venetoclax)
• hypomethylating agent therapy (azacitidine/decitabine)
• menin inhibitor therapy (revumenib/ziftomenib)

12. Prevention

Primary prevention of de novo NPM1-mutated AML is not established. Practical prevention in AML largely focuses on reducing therapy-related AML risk (when feasible) and optimizing supportive care to reduce infectious/hemorrhagic mortality; no NPM1-specific preventive interventions were retrieved in the evidence set for this run.

13. Other Species / Natural Disease

No naturally occurring NPM1-mutated AML analogs in non-human species were retrieved in this run.

14. Model Organisms / Experimental Models

14.1 Genetic mouse models

A 2023 primary study used a hematopoietic-specific conditional knock-in NPM1C+ mouse model and showed that NPM1C+ alters TAD topology and induces an MPN/MDS-like condition (long latency, splenomegaly, leukocytosis, thrombocytopenia), supporting its use as a mechanistic model for leukemogenesis and differentiation block. (lai2023npm1mutationreprograms pages 1-3)

14.2 Cell lines and PDX models

• OCI-AML3 (human NPM1-mutant AML) is used in mechanistic intervention experiments including XPO1 inhibition (selinexor) to restore nuclear NPM1 and reduce HOX/MEIS1 programs. (lai2023npm1mutationreprograms pages 1-3)
• Patient-derived xenograft (PDX) models and AML cell lines are used to test menin–MLL inhibitors (e.g., DS‑1594a preclinical work; multiple models including PDX). (numata2023anovelmeninmll1 pages 1-2)

Appendix: Key “expert opinion” / interpretive synthesis (grounded in authoritative sources)

1. Classification is converging on “AML-defining” genetics, but thresholds differ. WHO 2022’s no-blast-threshold stance for AML-defining genetics contrasts with ICC’s ≥10% cutoff, creating a gray zone for low-blast NPM1-mutated myeloid neoplasms. (falini2024criteriafordiagnosis pages 5-6, patel2024npm1mutatedacutemyeloid pages 4-4)
2. MRD is central for NPM1-mutated AML management across treatment intensities. MRD is presented as a key decision tool in diagnostic guidance and is strongly prognostic in contemporary venetoclax-treated cohorts; it also enables relapse-preemptive strategies. (falini2024criteriafordiagnosis pages 1-2, othman2024molecularmrdis pages 1-2, tiong2024targetingmolecularmeasurable pages 1-2)
3. Therapy is shifting from cytotoxic-only toward genotype-driven targeted combinations. Menin inhibition has first-in-human efficacy and is now being tested in large Phase 3 trials in both intensive and nonintensive backbones in NPM1-mutated AML. (issa2023themenininhibitor pages 1-2, NCT07211958 chunk 1, NCT07007312 chunk 1, NCT06652438 chunk 1)

Notes on evidence limitations

• This run did not retrieve ICD, MeSH, OMIM, Orphanet, or a disease-specific MONDO identifier for NPM1-mutated AML, and therefore these identifiers are not asserted here.
• Supportive care details (antibacterial/antifungal prophylaxis specifics) were not extracted into citable evidence within this run and are therefore not included as major claims.

References

1. (falini2024criteriafordiagnosis pages 1-2): Brunangelo Falini and Richard Dillon. Criteria for diagnosis and molecular monitoring of npm1-mutated aml. Blood Cancer Discovery, 5:8-20, Dec 2024. URL: https://doi.org/10.1158/2643-3230.bcd-23-0144, doi:10.1158/2643-3230.bcd-23-0144. This article has 40 citations and is from a peer-reviewed journal.

2. (patel2024npm1mutatedacutemyeloid pages 1-2): Sanjay S. Patel. Npm1-mutated acute myeloid leukemia: recent developments and open questions. Pathobiology, 91:18-29, Mar 2024. URL: https://doi.org/10.1159/000530253, doi:10.1159/000530253. This article has 23 citations and is from a peer-reviewed journal.

3. (falini2024criteriafordiagnosis pages 5-6): Brunangelo Falini and Richard Dillon. Criteria for diagnosis and molecular monitoring of npm1-mutated aml. Blood Cancer Discovery, 5:8-20, Dec 2024. URL: https://doi.org/10.1158/2643-3230.bcd-23-0144, doi:10.1158/2643-3230.bcd-23-0144. This article has 40 citations and is from a peer-reviewed journal.

4. (shimony2023acutemyeloidleukemia pages 5-6): Shai Shimony, Maximilian Stahl, and Richard M. Stone. Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management. American Journal of Hematology, 98:502-526, Jan 2023. URL: https://doi.org/10.1002/ajh.26822, doi:10.1002/ajh.26822. This article has 524 citations and is from a domain leading peer-reviewed journal.

5. (sargas2023comparisonofthe pages 1-2): Claudia Sargas, Rosa Ayala, María J. Larráyoz, María C. Chillón, Eduardo Rodriguez-Arboli, Cristina Bilbao, Esther Prados de la Torre, David Martínez-Cuadrón, Rebeca Rodríguez-Veiga, Blanca Boluda, Cristina Gil, Teresa Bernal, Juan Bergua, Lorenzo Algarra, Mar Tormo, Pilar Martínez-Sánchez, Elena Soria, Josefina Serrano, Juan M. Alonso-Dominguez, Raimundo García, María Luz Amigo, Pilar Herrera-Puente, María J. Sayas, Esperanza Lavilla-Rubira, Joaquín Martínez-López, María J. Calasanz, Ramón García-Sanz, José A. Pérez-Simón, María T. Gómez Casares, Joaquín Sánchez-García, Eva Barragán, Pau Montesinos, and Esther Prados de la Torre. Comparison of the 2022 and 2017 european leukemianet risk classifications in a real-life cohort of the pethema group. Blood Cancer Journal, May 2023. URL: https://doi.org/10.1038/s41408-023-00835-5, doi:10.1038/s41408-023-00835-5. This article has 38 citations and is from a domain leading peer-reviewed journal.

6. (lachowiez2023comparisonandvalidation pages 1-2): Curtis A. Lachowiez, Nicola Long, Jennifer Saultz, Arpita Gandhi, Laura F. Newell, Brandon Hayes-Lattin, Richard T. Maziarz, Jessica Leonard, Daniel Bottomly, Shannon McWeeney, Jennifer Dunlap, Richard Press, Gabrielle Meyers, Ronan Swords, Rachel J. Cook, Jeffrey W. Tyner, Brian J. Druker, and Elie Traer. Comparison and validation of the 2022 european leukemianet guidelines in acute myeloid leukemia. Blood Advances, 7:1899-1909, May 2023. URL: https://doi.org/10.1182/bloodadvances.2022009010, doi:10.1182/bloodadvances.2022009010. This article has 112 citations and is from a peer-reviewed journal.

7. (patel2024npm1mutatedacutemyeloid pages 4-4): Sanjay S. Patel. Npm1-mutated acute myeloid leukemia: recent developments and open questions. Pathobiology, 91:18-29, Mar 2024. URL: https://doi.org/10.1159/000530253, doi:10.1159/000530253. This article has 23 citations and is from a peer-reviewed journal.

8. (sharma2023npm1mutations pages 1-2): Naman Sharma and Jane L. Liesveld. Npm 1 mutations in aml—the landscape in 2023. Cancers, 15:1177, Feb 2023. URL: https://doi.org/10.3390/cancers15041177, doi:10.3390/cancers15041177. This article has 60 citations.

9. (mrozek2023outcomepredictionby pages 1-2): Krzysztof Mrózek, Jessica Kohlschmidt, James S. Blachly, Deedra Nicolet, Andrew J. Carroll, Kellie J. Archer, Alice S. Mims, Karilyn T. Larkin, Shelley Orwick, Christopher C. Oakes, Jonathan E. Kolitz, Bayard L. Powell, William G. Blum, Guido Marcucci, Maria R. Baer, Geoffrey L. Uy, Wendy Stock, John C. Byrd, and Ann-Kathrin Eisfeld. Outcome prediction by the 2022 european leukemianet genetic-risk classification for adults with acute myeloid leukemia: an alliance study. Leukemia, 37:788-798, Feb 2023. URL: https://doi.org/10.1038/s41375-023-01846-8, doi:10.1038/s41375-023-01846-8. This article has 82 citations and is from a highest quality peer-reviewed journal.

10. (chin2023targetingandmonitoring pages 1-2): Lynn Chin, Chantelle Ye Gwen Wong, and Harinder Gill. Targeting and monitoring acute myeloid leukaemia with nucleophosmin-1 (npm1) mutation. International Journal of Molecular Sciences, 24:3161, Feb 2023. URL: https://doi.org/10.3390/ijms24043161, doi:10.3390/ijms24043161. This article has 20 citations.

11. (othman2024molecularclinicaland pages 1-5): Jad Othman, Nicola Potter, Adam Ivey, Yanis Tazi, Elli Papaemmanuil, Jelena Jovanovic, Sylvie D. Freeman, Amanda Gilkes, Rosemary Gale, Tanya Rapoz-D’Silva, Manohursingh Runglall, Michelle Kleeman, Pawan Dhami, Ian Thomas, Sean Johnson, Joanna Canham, Jamie Cavenagh, Panagiotis Kottaridis, Claire Arnold, Hans Beier Ommen, Ulrik Malthe Overgaard, Mike Dennis, Alan Burnett, Charlotte Wilhelm-Benartzi, Brian Huntly, Nigel H. Russell, and Richard Dillon. Molecular, clinical, and therapeutic determinants of outcome in npm1-mutated aml. Blood, 144:714-728, Aug 2024. URL: https://doi.org/10.1182/blood.2024024310, doi:10.1182/blood.2024024310. This article has 86 citations and is from a highest quality peer-reviewed journal.

12. (papadopoulou2024characteristicsandprognosis pages 1-2): Vasiliki Papadopoulou, Giulia Schiavini, Gregoire Stalder, Valentin Basset, Jacqueline Schoumans, Mitja Nabergoj, and Muriel Schaller. Characteristics and prognosis of “acute promyelocytic leukemia-like” nucleophosmin-1-mutated acute myeloid leukemia in a retrospective patient cohort. Biomedicines, 12:2282, Oct 2024. URL: https://doi.org/10.3390/biomedicines12102282, doi:10.3390/biomedicines12102282. This article has 2 citations.

13. (patel2024npm1mutatedacutemyeloid pages 3-4): Sanjay S. Patel. Npm1-mutated acute myeloid leukemia: recent developments and open questions. Pathobiology, 91:18-29, Mar 2024. URL: https://doi.org/10.1159/000530253, doi:10.1159/000530253. This article has 23 citations and is from a peer-reviewed journal.

14. (lai2023npm1mutationreprograms pages 1-3): Qian Lai, Karina Hamamoto, Huacheng Luo, Zachary J Zaroogian, Caixian Zhou, Julia Lesperance, Jie Zha, Y. Qiu, O. Guryanova, Suming Huang, and Bing Xu. Npm1 mutation reprograms leukemic transcription network via reshaping tad topology. Leukemia, 37:1732-1736, Jun 2023. URL: https://doi.org/10.1038/s41375-023-01942-9, doi:10.1038/s41375-023-01942-9. This article has 11 citations and is from a highest quality peer-reviewed journal.

15. (patel2024npm1mutatedacutemyeloid pages 8-9): Sanjay S. Patel. Npm1-mutated acute myeloid leukemia: recent developments and open questions. Pathobiology, 91:18-29, Mar 2024. URL: https://doi.org/10.1159/000530253, doi:10.1159/000530253. This article has 23 citations and is from a peer-reviewed journal.

16. (patel2024npm1mutatedacutemyeloid pages 2-3): Sanjay S. Patel. Npm1-mutated acute myeloid leukemia: recent developments and open questions. Pathobiology, 91:18-29, Mar 2024. URL: https://doi.org/10.1159/000530253, doi:10.1159/000530253. This article has 23 citations and is from a peer-reviewed journal.

17. (othman2024molecularmrdis pages 1-2): Jad Othman, Ing S. Tiong, Jenny O'Nions, Mike Dennis, Katya Mokretar, Adam Ivey, Michael Austin, Anne-Louise Latif, Mariam Amer, Wei Yee Chan, Charles Crawley, Francesca Crolla, Joe Cross, Ray Dang, Johnathon Elliot, Chun Y. Fong, Sofia Galli, Paolo Gallipoli, Francesca Hogan, Pallavi Kalkur, Anjum Khan, Pramila Krishnamurthy, John Laurie, Sun Loo, Scott Marshall, Priyanka Mehta, Vidhya Murthy, Sateesh Nagumantry, Srinivas Pillai, Nicola Potter, Rob Sellar, Tom Taylor, Rui Zhao, Nigel H. Russell, Andrew H. Wei, and Richard Dillon. Molecular mrd is strongly prognostic in patients with npm1-mutated aml receiving venetoclax-based nonintensive therapy. Blood, 143:336-341, Jan 2024. URL: https://doi.org/10.1182/blood.2023021579, doi:10.1182/blood.2023021579. This article has 79 citations and is from a highest quality peer-reviewed journal.

18. (falini2024criteriafordiagnosis media 3d972561): Brunangelo Falini and Richard Dillon. Criteria for diagnosis and molecular monitoring of npm1-mutated aml. Blood Cancer Discovery, 5:8-20, Dec 2024. URL: https://doi.org/10.1158/2643-3230.bcd-23-0144, doi:10.1158/2643-3230.bcd-23-0144. This article has 40 citations and is from a peer-reviewed journal.

19. (shukla2024molecularfeaturesand pages 5-6): Mihir Shukla, Maher Abdul-Hay, and Jun H. Choi. Molecular features and treatment paradigms of acute myeloid leukemia. Biomedicines, 12:1768, Aug 2024. URL: https://doi.org/10.3390/biomedicines12081768, doi:10.3390/biomedicines12081768. This article has 6 citations.

20. (tiong2024targetingmolecularmeasurable pages 1-2): Ing Soo Tiong, Devendra K. Hiwase, Emad Abro, Ashish Bajel, Emma Palfreyman, Ashanka Beligaswatte, John Reynolds, Natasha Anstee, Tamia Nguyen, Sun Loo, Chong Chyn Chua, Michael Ashby, Kaitlyn M. Wiltshire, Shaun Fleming, Chun Y. Fong, Tse-Chieh Teh, Piers Blombery, Richard Dillon, Adam Ivey, and Andrew H. Wei. Targeting molecular measurable residual disease and low-blast relapse in aml with venetoclax and low-dose cytarabine: a prospective phase ii study (valdac). Journal of Clinical Oncology, 42:2161-2173, Jun 2024. URL: https://doi.org/10.1200/jco.23.01599, doi:10.1200/jco.23.01599. This article has 32 citations and is from a highest quality peer-reviewed journal.

21. (issa2023themenininhibitor pages 1-2): Ghayas C. Issa, Ibrahim Aldoss, John DiPersio, Branko Cuglievan, Richard Stone, Martha Arellano, Michael J. Thirman, Manish R. Patel, David S. Dickens, Shalini Shenoy, Neerav Shukla, Hagop Kantarjian, Scott A. Armstrong, Florian Perner, Jennifer A. Perry, Galit Rosen, Rebecca G. Bagley, Michael L. Meyers, Peter Ordentlich, Yu Gu, Vinit Kumar, Steven Smith, Gerard M. McGeehan, and Eytan M. Stein. The menin inhibitor revumenib in kmt2a-rearranged or npm1-mutant leukaemia. Nature, 615:920-924, Mar 2023. URL: https://doi.org/10.1038/s41586-023-05812-3, doi:10.1038/s41586-023-05812-3. This article has 522 citations and is from a highest quality peer-reviewed journal.

22. (issa2023themenininhibitor pages 4-4): Ghayas C. Issa, Ibrahim Aldoss, John DiPersio, Branko Cuglievan, Richard Stone, Martha Arellano, Michael J. Thirman, Manish R. Patel, David S. Dickens, Shalini Shenoy, Neerav Shukla, Hagop Kantarjian, Scott A. Armstrong, Florian Perner, Jennifer A. Perry, Galit Rosen, Rebecca G. Bagley, Michael L. Meyers, Peter Ordentlich, Yu Gu, Vinit Kumar, Steven Smith, Gerard M. McGeehan, and Eytan M. Stein. The menin inhibitor revumenib in kmt2a-rearranged or npm1-mutant leukaemia. Nature, 615:920-924, Mar 2023. URL: https://doi.org/10.1038/s41586-023-05812-3, doi:10.1038/s41586-023-05812-3. This article has 522 citations and is from a highest quality peer-reviewed journal.

23. (NCT07211958 chunk 1): Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation. Syndax Pharmaceuticals. 2025. ClinicalTrials.gov Identifier: NCT07211958

24. (NCT06652438 chunk 1): Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML. Stichting Hemato-Oncologie voor Volwassenen Nederland. 2025. ClinicalTrials.gov Identifier: NCT06652438

25. (NCT07007312 chunk 1): Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML. Kura Oncology, Inc.. 2025. ClinicalTrials.gov Identifier: NCT07007312

26. (othman2024molecularmrdis pages 7-8): Jad Othman, Ing S. Tiong, Jenny O'Nions, Mike Dennis, Katya Mokretar, Adam Ivey, Michael Austin, Anne-Louise Latif, Mariam Amer, Wei Yee Chan, Charles Crawley, Francesca Crolla, Joe Cross, Ray Dang, Johnathon Elliot, Chun Y. Fong, Sofia Galli, Paolo Gallipoli, Francesca Hogan, Pallavi Kalkur, Anjum Khan, Pramila Krishnamurthy, John Laurie, Sun Loo, Scott Marshall, Priyanka Mehta, Vidhya Murthy, Sateesh Nagumantry, Srinivas Pillai, Nicola Potter, Rob Sellar, Tom Taylor, Rui Zhao, Nigel H. Russell, Andrew H. Wei, and Richard Dillon. Molecular mrd is strongly prognostic in patients with npm1-mutated aml receiving venetoclax-based nonintensive therapy. Blood, 143:336-341, Jan 2024. URL: https://doi.org/10.1182/blood.2023021579, doi:10.1182/blood.2023021579. This article has 79 citations and is from a highest quality peer-reviewed journal.

27. (othman2024molecularmrdis pages 5-6): Jad Othman, Ing S. Tiong, Jenny O'Nions, Mike Dennis, Katya Mokretar, Adam Ivey, Michael Austin, Anne-Louise Latif, Mariam Amer, Wei Yee Chan, Charles Crawley, Francesca Crolla, Joe Cross, Ray Dang, Johnathon Elliot, Chun Y. Fong, Sofia Galli, Paolo Gallipoli, Francesca Hogan, Pallavi Kalkur, Anjum Khan, Pramila Krishnamurthy, John Laurie, Sun Loo, Scott Marshall, Priyanka Mehta, Vidhya Murthy, Sateesh Nagumantry, Srinivas Pillai, Nicola Potter, Rob Sellar, Tom Taylor, Rui Zhao, Nigel H. Russell, Andrew H. Wei, and Richard Dillon. Molecular mrd is strongly prognostic in patients with npm1-mutated aml receiving venetoclax-based nonintensive therapy. Blood, 143:336-341, Jan 2024. URL: https://doi.org/10.1182/blood.2023021579, doi:10.1182/blood.2023021579. This article has 79 citations and is from a highest quality peer-reviewed journal.

28. (numata2023anovelmeninmll1 pages 1-2): Masashi Numata, Noriyasu Haginoya, Machiko Shiroishi, Tsuyoshi Hirata, Aiko Sato-Otsubo, Kenji Yoshikawa, Yoshimi Takata, Reina Nagase, Yoshinori Kashimoto, Makoto Suzuki, Nina Schulte, Gernot Polier, Akiko Kurimoto, Yumiko Tomoe, Akiko Toyota, Tomoko Yoneyama, Emi Imai, Kenji Watanabe, Tomoaki Hamada, Ryutaro Kanada, Jun Watanabe, Yoshiko Kagoshima, Eri Tokumaru, Kenji Murata, Takayuki Baba, Taeko Shinozaki, Masami Ohtsuka, Koichi Goto, Tsuyoshi Karibe, Takao Deguchi, Yoshihiro Gocho, Masanori Yoshida, Daisuke Tomizawa, Motohiro Kato, Shinji Tsutsumi, Mayumi Kitagawa, and Yuki Abe. A novel menin-mll1 inhibitor, ds-1594a, prevents the progression of acute leukemia with rearranged mll1 or mutated npm1. Cancer Cell International, Feb 2023. URL: https://doi.org/10.1186/s12935-023-02877-y, doi:10.1186/s12935-023-02877-y. This article has 34 citations and is from a peer-reviewed journal.